Data completeness
2/8 — Basic
IOMERVU by Bracco is intra-arterial administration, permitting radiographic visualization of the internal structures through attenuation of x-ray photons. First approved in 2024.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IOMERVU is an iodinated contrast agent administered intravenously for radiographic visualization of internal body structures through X-ray attenuation. It works by diffusing from vessels into extravascular space in regions of disrupted blood-brain barrier, enabling enhanced imaging of pathological lesions. The product is indicated for diagnostic imaging applications where vascular and tissue visualization is clinically necessary.
Growth3.6 years to LOE
Recently approved product entering growth phase with established sponsor infrastructure; early-stage team building underway with modest initial market penetration expected.
Mechanism of Action
intra-arterial administration, permitting radiographic visualization of the internal structures through attenuation of X-ray photons. In imaging of the body, iodinated contrast agents diffuse from the vessels into the extravascular space. In normal brain with an intact blood-brain barrier, the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Worked on IOMERVU at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.